Johnson & Johnson (NYSE: JNJ) released strong fourth-quarter 2025 earnings, with sales up 9.1% to $24.6 billion and adjusted earnings per share up 20.6% to $2.46. The company projects $100-$101 billion in sales for fiscal year 2026, a historic milestone as it would be the first time it achieves $100 billion in annual sales. Johnson & Johnson’s ability to navigate challenges like patent cliffs and government drug price negotiations showcases its strong underlying business. The healthcare giant’s diverse lineup and pipeline, along with its medtech division, position it for long-term success and sustain its outstanding dividend program.

Read more at Nasdaq: This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?